Skye Bioscience (SKYE) EBITDA (2012 - 2026)
Skye Bioscience (SKYE) posted quarterly EBITDA of -$12.7 million for Q1 2026, down 7.78% year-over-year from -$13.7 million in Q1 2025, and up 14.91% quarter-over-quarter from -$14.9 million in Q4 2025.
Skye Bioscience (SKYE) EBITDA (2012 - 2026) Analysis & Trends
Skye Bioscience (SKYE) has reported EBITDA for 15 consecutive years, with -$12.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA fell 7.78% year-over-year to -$12.7 million; the TTM figure through Mar 2026 stood at -$59.1 million (down 65.02% YoY), while the FY2025 annual figure was -$58.2 million, down 92.64% from the prior year.
- EBITDA climbed to -$12.7 million in Q1 2026 per SKYE's latest filing, from -$14.9 million in the prior quarter.
- Across five years, EBITDA topped out at -$2.8 million in Q2 2023 and bottomed at -$24.7 million in Q3 2023.
- Historically, EBITDA has averaged -$9.1 million across 5 years, with a median of -$8.4 million in 2024.
- Annual changes were most pronounced in 2023 — EBITDA slumped 745.43% — and 2024, when it soared 79.89%.
- Skye Bioscience's EBITDA stood at -$9.3 million in 2022, then jumped by 55.98% to -$4.1 million in 2023, then tumbled by 161.02% to -$10.7 million in 2024, then slumped by 39.65% to -$14.9 million in 2025, then rose by 14.91% to -$12.7 million in 2026.
- Business Quant data shows SKYE's EBITDA at -$12.7 million in Q1 2026, -$14.9 million in Q4 2025, and -$13.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Skye Bioscience | 11.17 Mn | 11.17 Mn | - | -11.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.67 Mn |
| Dec 31, 2025 | -14.90 Mn |
| Sep 30, 2025 | -13.26 Mn |
| Jun 30, 2025 | -18.24 Mn |
| Mar 31, 2025 | -11.76 Mn |
| Dec 31, 2024 | -10.67 Mn |
| Sep 30, 2024 | -4.97 Mn |
| Jun 30, 2024 | -8.41 Mn |
| Mar 31, 2024 | -6.15 Mn |
| Dec 31, 2023 | -4.09 Mn |
| Sep 30, 2023 | -24.71 Mn |
| Jun 30, 2023 | -2.84 Mn |
| Mar 31, 2023 | -3.10 Mn |
| Dec 31, 2022 | -9.28 Mn |
| Sep 30, 2022 | -2.92 Mn |
| Jun 30, 2022 | -3.22 Mn |
| Mar 31, 2022 | -2.89 Mn |
| Dec 31, 2021 | -2.46 Mn |
| Sep 30, 2021 | -1.82 Mn |
| Jun 30, 2021 | -1.83 Mn |